PRTA

Prothena Corporation plc
CAPPED RATING

Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, which is in Phase IIb clinical trial for the treatment of Parkinson's disease; PRX004 that completed Phase I clinical trial for the treatment of Transthyretin amyloidosis; and PRX005, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX012 for the treatment of Alzheimer's disease; and dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein; and a collaboration agreement with Bristol-Myers Squibb to develop antibodies. The company was founded in 2012 and is based in Dublin, Ireland.

Prothena Corporation plc (PRTA) is rated C (2.3/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Profitability (B); its weakest is Growth (F). The rating has held at C for 5 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
2.3 / 5.0
C
Value
B-
Factor Score 3.0 / 5.0
Growth
F
Factor Score 0.2 / 5.0
Profitability
B
Factor Score 3.2 / 5.0
Momentum
C+
Factor Score 2.6 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -6.6
EV / EBITDA -4.1
Rev Growth YoY -74.3%
Gross Margin 15.7%
Price Return 3M -8.1%
Price Return 12M -24.8%
Catalyst Signal 0.00
Market Cap $419.0M
TTM Revenue $52.7M
Price / Sales 7.9
ROE -8.5%

Historical Factor Score Progression

Held C for 5 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-14 B- (3.0) F (0.2) B (3.2) C+ (2.6) C+ (2.6) C (2.3)
2026-11-07 B- (3.0) F (0.2) B (3.2) C (2.4) C+ (2.7) C (2.3)
2026-10-31 B- (3.0) F (0.2) B- (2.9) C+ (2.5) C+ (2.7) C (2.3)
2026-10-24 B- (3.0) F (0.2) B- (2.9) C (2.2) C+ (2.6) C (2.2)
2026-10-17 B- (3.0) F (0.2) B- (2.9) C (2.3) C+ (2.6) C (2.2)
Page 1 of 8
…